Wave Life Sciences, Inc. (WVE)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $3.14
- As of
Kresmion compiles this page from WVE's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Wave Life Sciences, Inc. (WVE): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-07-30.
See the full WVE dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for WVE on one page. Preview it with sample data, then open it live with a free account.
Preview the WVE dossierActive signals for WVE
- highCONSENSUS_SELL
4 tracked funds reduced WVE this 2026Q2, institutional consensus
- highCONSENSUS_BUY
5 tracked funds increased WVE this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 91% of WVE (2026Q2)
- highCONSENSUS_BUY
4 tracked funds increased WVE this 2026Q2, institutional consensus
- highINSTITUTIONAL_EXIT
Point72 Asset Management, L.P. cut 92% of WVE (2026Q2)
FREE, NO ACCOUNT
Every signal on WVE, as it fires
You are seeing 5 of 15 signals recorded on WVE since 2026-05-26.
The five above landed across 2 days. The other 10 were recorded on 2 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in WVE (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| TWO SIGMA INVESTMENTS, LPCUSIP Y95308105 · 2026Q2 | $21.5M | 0.02% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP Y95308105 · 2026Q2 | $10.5M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP Y95308105 · 2026Q2 | $10.3M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP Y95308105 · 2026Q2 | $9.9M | 0.01% | , |
| Point72 Asset Management, L.P.CUSIP Y95308105 · 2026Q2 | $8.6M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP Y95308105 · 2026Q2 | $2.8M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, WVE
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
WVE against its peers
WVE's operating margin of -504.1% ranks in the 30th percentile of 14 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | WVE | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 42.7M USD | 106M USD | 39 | 13 |
| Operating margin | -504.1% | -53.1% | 30 | 14 |
| Net margin | -478.3% | -32.6% | 30 | 14 |
| Return on equity | -39.4% | -52.5% | 55 | 20 |
| P / E | n/a | 14.7x | n/a | 5 |
| 1 year | -59.7% | -2.8% | 3 | 19 |
Peers (22): OLMA, PRME, AURA, ZVRA, CLYM, IRWD, PHAR, VSTM, STTK, SGMT, MDXG, DBVT, XOMA, NVCT, CADL, FDMT, SLDB, PHAT, ACHV, GYRE, CRMD, VALN. Left out: BLSM (no annual filing), IVA (period gap), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (WVE: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow WVE on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to WVE for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.